A partial digest of what we learned: Holy vaccine, Act II. The good news: Not only did Moderna come through with some exceptional early-look news of its own—94.5% efficacy for their mRNA vaccine—but upon completion of the Pfizer-BioNTech study, the latter partnership’s final figure is
11202020 :: Friday finance week in review
11202020 :: Friday finance week in review
11202020 :: Friday finance week in review
A partial digest of what we learned: Holy vaccine, Act II. The good news: Not only did Moderna come through with some exceptional early-look news of its own—94.5% efficacy for their mRNA vaccine—but upon completion of the Pfizer-BioNTech study, the latter partnership’s final figure is